Literature DB >> 32145187

Has China faced only a herald wave of SARS-CoV-2?

Antoine Flahault1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32145187      PMCID: PMC7124610          DOI: 10.1016/S0140-6736(20)30521-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
The attack rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calculated by mathematical models, from estimates of the basic reproduction number, R0, of 2–3, suggests that 50–60% of the population should eventually be infected because the population seems to be entirely naive to the new virus. The observed attack rate on board the Diamond Princess cruise ship remained slightly below 20% (705 of 3711 passengers and crew members became infected). It is of upmost importance to know whether the SARS-CoV-2 outbreak in China is subsiding, as local authorities and the entire international community might wish. With 80 026 COVID-19 cases officially reported from China as of March 2, 2020, the proportion of the population affected remains far from 50%, or even 20%, of China's 1·4 billion people. Has China just experienced a herald wave, to use terminology borrowed from those who study tsunamis, and is the big wave still to come? Serosurveys can help answer these questions precisely. To serosurvey the outbreak would involve testing sera of blood samples from the most representative sample of the population at the epicentre of the epidemic, Wuhan. Serology analysis with neutralising antibodies from the 1000 people could allow for the rate of SARS-CoV-2 infections to be estimated with good accuracy. This rate could be extrapolated to the city's entire population and thus inform more precisely whether the provisional attack rate during this period was a few cases per thousand or perhaps affected 1–2% of the population, 20%, or more. Serosurveys should be seen as polls before elections; they can be repeated several times, week after week, to monitor the epidemic precisely. There is no reason to wait for the end of the epidemic before doing serosurveys. The results would be tremendously informative to China, first and foremost, and to the entire international community, on the risk of big secondary epidemic waves.
  2 in total

1.  Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.

Authors:  Joseph T Wu; Kathy Leung; Gabriel M Leung
Journal:  Lancet       Date:  2020-01-31       Impact factor: 79.321

2.  Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: two methods for two critical times of the epidemic.

Authors:  Patrick Gérardin; Vanina Guernier; Joëlle Perrau; Adrian Fianu; Karin Le Roux; Philippe Grivard; Alain Michault; Xavier de Lamballerie; Antoine Flahault; François Favier
Journal:  BMC Infect Dis       Date:  2008-07-28       Impact factor: 3.090

  2 in total
  14 in total

1.  Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study.

Authors:  Kelvin Kai-Wang To; Vincent Chi-Chung Cheng; Jian-Piao Cai; Kwok-Hung Chan; Lin-Lei Chen; Lok-Hin Wong; Charlotte Yee-Ki Choi; Carol Ho-Yan Fong; Anthony Chin-Ki Ng; Lu Lu; Cui-Ting Luo; Jianwen Situ; Tom Wai-Hin Chung; Shuk-Ching Wong; Grace See-Wai Kwan; Siddharth Sridhar; Jasper Fuk-Woo Chan; Cecilia Yuen-Man Fan; Vivien W M Chuang; Kin-Hang Kok; Ivan Fan-Ngai Hung; Kwok-Yung Yuen
Journal:  Lancet Microbe       Date:  2020-06-03

2.  Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19.

Authors:  Pradeep Singh Cheema; Deeptashree Nandi; Alo Nag
Journal:  Open Biol       Date:  2021-06-09       Impact factor: 6.411

3.  A prospect on the use of antiviral drugs to control local outbreaks of COVID-19.

Authors:  Andrea Torneri; Pieter Libin; Joris Vanderlocht; Anne-Mieke Vandamme; Johan Neyts; Niel Hens
Journal:  BMC Med       Date:  2020-06-25       Impact factor: 8.775

Review 4.  Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19.

Authors:  Russel J Reiter; Pedro Abreu-Gonzalez; Paul E Marik; Alberto Dominguez-Rodriguez
Journal:  Front Med (Lausanne)       Date:  2020-05-15

Review 5.  Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19?

Authors:  Syeda Anum Zahra; Sashini Iddawela; Kiran Pillai; Rozina Yasmin Choudhury; Amer Harky
Journal:  Brain Behav       Date:  2020-09-16       Impact factor: 2.708

6.  National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance.

Authors:  Muthusamy Santhosh Kumar; Tarun Bhatnagar; Ponnaiah Manickam; V Saravana Kumar; Kiran Rade; Naman Shah; Shashi Kant; Giridhara R Babu; Sanjay Zodpey; C P Girish Kumar; Jeromie Wesley Vivian Thangaraj; Pranab Chatterjee; Suman Kanungo; Ravindra Mohan Pandey; Manoj Murhekar; Sujeet K Singh; Swarup Sarkar; J P Muliyi; Raman R Gangakhedkar; D C S Reddy
Journal:  Indian J Med Res       Date:  2020-05       Impact factor: 2.375

Review 7.  SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Ranjit Sah; Ruchi Tiwari; Mohd Iqbal Yatoo; Shailesh Kumar Patel; Mamta Pathak; Yashpal Singh Malik; Kuldeep Dhama; Karam Pal Singh; D Katterine Bonilla-Aldana; Shafiul Haque; Dayron F Martinez-Pulgarin; Alfonso J Rodriguez-Morales; Hakan Leblebicioglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-09-02       Impact factor: 3.944

8.  COVID-19 and rationally layered social distancing.

Authors:  Richard A Stein
Journal:  Int J Clin Pract       Date:  2020-04-06       Impact factor: 3.149

Review 9.  Biochemical parameters and pathogenesis of SARS-CoV-2 infection in vital organs: COVID-19 outbreak in Iran.

Authors:  S Mirmohammadi; A Kianmehr; M Arefi; A Mahrooz
Journal:  New Microbes New Infect       Date:  2020-10-17

10.  Failure in initial stage containment of global COVID-19 epicenters.

Authors:  Veria Khosrawipour; Hien Lau; Tanja Khosrawipour; Piotr Kocbach; Hirohito Ichii; Jacek Bania; Agata Mikolajczyk
Journal:  J Med Virol       Date:  2020-04-28       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.